

A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Published: 01-04-2010

Last updated: 03-05-2024

Primary objective To evaluate the relationship of incremental doses of NVA237 q.d. and b.i.d. and their effect on trough FEV1 after 28 days of treatment, as defined by the percentage of the maximal effect that each dose achieves in relation to the...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Respiratory disorders NEC
Study type	Interventional

Summary

ID

NL-OMON34643

Source

ToetsingOnline

Brief title

CNVA237A2208

Condition

- Respiratory disorders NEC

Synonym

chronic obstructive pulmonary disease, COPD

Research involving

Human

Sponsors and support

Primary sponsor: Novartis

Source(s) of monetary or material Support: Novartis Pharma BV

Intervention

Keyword: COPD, dose finding, NVA237

Outcome measures

Primary outcome

Relationship of incremental doses of NVA237 q.d. and b.i.d. and their effect on trough FEV1 after 28 days of treatment, as defined by the percentage of the maximal effect that each dose achieves in relation to the maximal effect of NVA237. (Trough is defined as the mean of FEV1 measurements at 23 h 15 min and 23 h 45 min post morning dose).

Secondary outcome

Use of rescue medication, FEV1 (AUC 0-24 h and shorter intervals, peak and 12 h), FVC, safety.

Study description

Background summary

NVA237 is a synthetic quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors and is being developed as a once-daily inhalation treatment to be delivered by the Novartis Single Dose Dry Powder Inhaler (SDDPI) for patients with COPD. Inhaled anticholinergic drugs such as ipratropium bromide (Atrovent®) and Tiotropium bromide (Spiriva®) have been approved in the US and European Union for the

treatment of COPD.

This study is designed to support the registration of NVA237 worldwide, including the US and the EU.

Study objective

Primary objective

To evaluate the relationship of incremental doses of NVA237 q.d. and b.i.d. and their effect on trough FEV1 after 28 days of treatment, as defined by the percentage of the maximal effect that each dose achieves in relation to the maximal effect of NVA237. (Trough is defined as the mean of FEV1 measurements at 23 h 15 min and 23 h 45 min post morning dose).

Key secondary objective

To evaluate the magnitude of any difference of effect on trough FEV1 after 28 days of treatment between the same total daily doses of NVA237 by comparing once daily and twice daily dosing regimens.

Study design

Randomized, double blind, placebo controlled cross over phase II study . 8 treatments, balanced incomplete block design. qd or bid dosing. Pre-screening, s.n. adjustment current COPD treatment, followed by 2nd screening and 1 week run-in period. Thereafter randomization to 16 independent treatment sequences. All patients will be given 2 treatments, separated by a washout period of 1 week.

Treatments:

1. Qd NVA237 12,5 mcg
2. Qd NVA237 25 mcg
3. Qd NVA237 50 mcg
4. Qd daags NVA237 100 mcg
5. Bid NVA237 12,5 mcg
6. BidNVA237 25 mcg
7. Bid NVA237 50 mcg
8. Placebo.

via single dose powder inhaler.

Salbutamol rescue medication.

Total study duration approx. 11 weeks.

Approx. 360 randomized patients (>500 screened).

Intervention

NVA237 or placebo.

Study burden and risks

Risks: Adverse events of study medication. Changes in current COPD medication.

Burden: 11-12 visits in 11 weeks, thereof 6 days of 24 h measurements (incl. hotel overnight stay) and 2 days of 9h measurements. Daily diary. Safety blood 3x. Approx. 10 ml blood per visit, total volume ca. 30 ml. Pregnancy test 2x. Normal visits: 3x. Vital signs (plus or minus physical exam) 1 visit. Pulmonary function tests 2x per visit (1 visit with reversibility). EKG 1 visit. 9h visits: 2x. Duration 9h. 6x pulmonary function tests. 1x vital signs. 24h visits: 6x. Duration 24h. 6x overnight stay in hotel with nightly measurements. 14-17 pulm. function tests. 0-1 EKG and 1-3x vital signs per visit.

Contacts

Public

Novartis

Raapopseweg 1
6824 DP Arnhem
NL

Scientific

Novartis

Raapopseweg 1
6824 DP Arnhem
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

1. Male or female adults aged 40 years and above.

4 - A randomized, double-blind, placebo-controlled, 2-period, cross-over study to as ... 4-05-2025

2. Moderate to severe stable COPD (Stage II or Stage III) according to the (GOLD Guidelines 2008).
3. Smoking history of at least 10 pack years.
4. Post-bronchodilator FEV1 >30% and < 80% of the predicted normal.
5. FEV1/FVC ratio <70% (post bronchodilation).

Exclusion criteria

- Lower airway infection in the past 4 weeks.
- Bronchial asthma.
- Type I and uncontrolled type II diabetes.
- α 1-antitrypsin deficiency.
- Other relevant pulmonary diseases.
- Contra-indications for anticholinergics.
- Use of ceratin COPD and other medications (see protocol for details).
- Vaccination with live or inactivated vaccines in the past 30 and 2 days resp.
- Longterm oxygen therapy.
- Pregnancy and breast feeding. Inadequate contraception, if relevant.

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Crossover
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	09-06-2010
Enrollment:	58
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	NVA237
Generic name:	NVA237

Ethics review

Approved WMO	
Date:	01-04-2010
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO	
Date:	15-04-2010
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO	
Date:	18-05-2010
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO	
Date:	25-05-2010
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO	
Date:	26-05-2010
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO	
Date:	17-06-2010
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO
Date: 16-08-2010
Application type: Amendment
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO
Date: 24-08-2010
Application type: Amendment
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO
Date: 03-09-2010
Application type: Amendment
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
Other	clinicaltrials.gov, registratienummer nog niet bekend
EudraCT	EUCTR2009-014038-11-NL
CCMO	NL31828.060.10